Madrid

• Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacok … Ended
  2024-510582-42-02 4 2025-08-14 Acute graft versus host disease (aGvHD)
• A study to investigate safety of INT2104 infusions in participants aged 18 years of age and older who have B-cell cancers that came back aft … Ended
  2023-509132-26-00 1 2025-08-08 Refractory/Relapsing B-Cell Malignancies
• Bioequivalence clinical trial of two formulations of loperamide. Ended
  2025-521549-26-00 2 2025-07-02 Healthy volunteers
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis Ended
  2024-513440-29-00 10 2025-06-25 Sickle cell disease vaso-occlusive crisis
• Randomised, crossover bioequivalence clinical trial of edoxaban 60 mg tablets versus edoxaban 60 mg film-coated tablets, after a single oral … Ended
  2025-522225-35-00 2 2025-06-23 Healthy volunteers
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patien … Ended
  2024-517322-26-00 1 2025-06-06 EGFR-Mutant Non-Small Cell Lung Cancer
• A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers. Ended
  2023-508759-38-00 1 2025-06-04 Relapsed/Refractory B-cell Malignancies
• Bioequivalence clinical trial of two formulations of dapagliflozin/metformin Ended
  2024-514050-75-01 2 2025-06-04 Healthy volunteers
• A study to learn about the study medicine called PF-08046032 in people with advanced cancers. Ended
  2024-517756-35-00 3 2025-05-28 Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell
• A Study to Investigate the Safety and Effectiveness of RO7759065 in Combination with Atezolizumab in Participants with Locally Advanced or M … Ended
  2024-513391-17-00 1 2025-05-27 Locally Advanced or Metastatic Solid Tumors
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DG … Ended
  2023-503996-38-00 1 2025-05-21 Advanced or metastatic solid tumors
• A Phase 2 Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2024-516889-11-00 4 2025-05-21 non-small cell lung cancer (NSCLC)
• A Phase 1 Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma Ended
  2024-513439-25-00 1 2025-04-30 Relapsed/Refractory Multiple Myeloma
• A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of … Ended
  2024-517814-13-00 4 2025-04-30 Moderate to Severe Atopic Dermatitis
• A long-term trial to learn about the safety of carbetocin as treatment for uncontrollable hunger in people with Prader-Willi Syndrome Ended
  2023-506201-19-00 5 2025-04-28 Hyperphagia related behaviour associated with Prader-Willi Syndrome (P
• A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KR … Ended
  2024-516699-14-00 7 2025-04-23 Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenoca
• A dosimetry study of lutetium (177Lu) rhPSMA-10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metas … Ended
  2024-515264-31-00 3 2025-04-15 PSMA-positive non-curative metastatic castration-resistant prostate ca
• A Study of Eciskafusp Alfa and Bacillus Calmette-Guérin (BCG) in Participants with High-Risk Bladder Cancer Unresponsive to BCG Treatment Ended
  2024-515410-41-00 9 2025-04-01 BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
• A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 Ended
  2024-515452-20-00 4 2025-04-01 Narcolepsy Type 2
• A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Th … Ended
  2024-515539-31-00 4 2025-04-01 Alzheimer’s disease dementia
• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• Randomised, crossover bioequivalence clinical trial of escitalopram 20 mg capsules versus escitalopram 20 mg film-coated tablets, after a si … Ended
  2025-521069-28-00 2 2025-03-21 Antidepressants
• Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors Ended
  2024-513563-75-00 1 2025-03-20 Metastatic or advanced malignant solid tumors
• A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together with Either Pembrolizumab, Standard Therapies, or Both, in Adults with Solid T … Ended
  2023-505084-37-00 7 2025-03-17 Advanced Solid Tumors

Showing 2,641–2,664 of 3,550 trials